NCT05238337

A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200 Following a Single Oral Dose in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Pyramid Biosciences · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, open-label non-randomized, single dose study in healthy male subjects.

Detailed description

This is a Phase 1, open-label nonrandomized, single dose study in healthy male subjects to determine the absorption, metabolism, and excretion (AME) of \[14C\]-PBI-200

Conditions

• Absorption, Metabolism and Excretion in Healthy Volunteers

Interventions

Type	Name	Description
DRUG	[14C]-PBI-200	\[14C\]-radio-labeled-PBI-200

Timeline

• Start date: 2022-02-24
• Primary completion: 2022-03-24
• Completion: 2022-03-24
• First posted: 2022-02-14
• Last updated: 2022-08-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study